Search hospitals > Massachusetts > Methuen
Dana-Farber Cancer Institute - Merrimack Valley
Claim this profileMethuen, Massachusetts 01844
Conducts research for Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Patient Adherence
Conducts research for Treatment Adherence and Compliance
3 reported clinical trials
3 medical researchers
Summary
Dana-Farber Cancer Institute - Merrimack Valley is a medical facility located in Methuen, Massachusetts. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Patient Adherence, Treatment Adherence and Compliance and other specialties. Dana-Farber Cancer Institute - Merrimack Valley is involved with conducting 3 clinical trials across 11 conditions. There are 3 research doctors associated with this hospital, such as Pedro M. Sanz-Altamira, Pedro Manuel Sanz-Altamira, and Leticia Varella, MD.Area of expertise
1Breast Cancer
Stage I
Stage II
ER positive
2Lung Cancer
Stage IV
KRAS positive
PD-L1 positive
Top PIs
Pedro M. Sanz-AltamiraDana Farber-Merrimack Valley2 years of reported clinical research
Studies Breast Cancer
Studies Lung Cancer
18 reported clinical trials
38 drugs studied
Pedro Manuel Sanz-AltamiraDana-Farber Cancer Institute - Merrimack Valley3 years of reported clinical research
Studies Breast Cancer
1 reported clinical trial
5 drugs studied
Leticia Varella, MDDana-Farber Cancer Institute3 years of reported clinical research
Studies Noncompliance
Studies Treatment Refusal
1 reported clinical trial
1 drug studied
Clinical Trials running at Dana-Farber Cancer Institute - Merrimack Valley
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria
CDK4/6 Inhibitors
for Metastatic Breast Cancer
The purpose of this study is to generate evidence on an alternative dosing strategy for CDK4/6 inhibitors to help more patients with Metastatic Breast Cancer (MBC) (age ≥ 65 years) tolerate side effects and stay on treatment longer, to derive the most clinical benefit from these drugs. The primary objective of the CDK Study is to compare time to treatment discontinuation (TTD) on the approved dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle) or ribociclib (600 mg orally daily on days 1-21 of 28-day cycle) vs. TTD using titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) or ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice endocrine therapy (aromatase inhibitor (AI) or fulvestrant) in patients age 65 or older with HR+/HER2- MBC. The secondary and exploratory objectives will generate evidence needed to personalize treatment decisions by comparing patient-centric secondary outcomes and evaluating baseline factors. Together with their treating physician, participants will choose the CDK4/6 inhibitor (palbociclib or ribociclib) and which endocrine therapy (aromatase inhibitor or fulvestrant) of their choice but will be randomized to either Arm 1 (indicated dosing) or Arm 2 (titrated dosing). Note: Telehealth visits are allowed at any time per institutional guidelines. In addition, the study allows for remote consenting per institutional guidelines.
Recruiting2 awards Phase 33 criteria
Elacestrant
for Breast Cancer
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Recruiting2 awards Phase 33 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Dana-Farber Cancer Institute - Merrimack Valley?
Dana-Farber Cancer Institute - Merrimack Valley is a medical facility located in Methuen, Massachusetts. This center is recognized for care of Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Patient Adherence, Treatment Adherence and Compliance and other specialties. Dana-Farber Cancer Institute - Merrimack Valley is involved with conducting 3 clinical trials across 11 conditions. There are 3 research doctors associated with this hospital, such as Pedro M. Sanz-Altamira, Pedro Manuel Sanz-Altamira, and Leticia Varella, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.